Lupin Limited has informed the Exchange about press release dated 22-Sep-2022 titled Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w.
Lupin Limited has informed the Exchange about press release dated 22-Sep-2022 titled Lupin Receives Approval from U.S. FDA for Diclofenac Sodium Topical Solution USP, 2% w/w.